Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection

in recovered COVID-19 patients: studies based on cellular and

structural biology analysis

- Fan Wu^{1*#}, Renhong Yan^{2,3#}, Mei Liu^{1#}, Zezhong Liu^{1#}, Yingdan Wang^{1#}, Die Luan¹, 5
- Kaiyue Wu¹, Zhigang Song¹, Tingting Sun¹, Yunping Ma¹, Yuanyuan Zhang^{2,3}, Qimin 6
- 7 Wang¹, Xiang Li¹, Ping Ji¹, Yaning Li⁴, Cheng Li¹, Yanling Wu¹, Tianlei Ying¹, Yumei
- Wen¹, Shibo Jiang¹, Tongyu Zhu^{1*}, Lu Lu^{1*}, Yongzhen Zhang^{1*}, Qiang Zhou^{2,3*}, Jinghe 8
- Huang^{1*} 9

1

2

3

4

10

20

28

30

- 11 ¹ Shanghai Public Health Clinical Center and Key Laboratory of Medical Molecular Virology
- 12 (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China.
- 13 ² Center for Infectious Disease Research, Zhejiang Provincial Laboratory of Life Sciences and
- Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, 14
- 15 Westlake University, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China.
- ³Institute of Biology, Westlake Institute for Advanced Study, 18 Shilongshan Road, Hangzhou 16
- 310024, Zhejiang Province, China. 17
- ⁴Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life 18
- 19 Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China.
- 21 #These authors contributed equally.
- *Correspondence Jinghe 86-21-37990333-7326, Email: 22 to: Dr. Huang,
- Jinghehuang@fudan.edu.cn; Fan Wu, 86-21-37990333-5295, Email: 23 Dr.
- wufan@fudan.edu.cn; Qiang Zhou, 86-0571-87969653, Email: 24 Dr.
- zhouqiang@westlake.edu.cn; Dr. Yongzheng Zhang, 86-21-37990333, 25 Email:
- zhangyongzhen@shphc.org.cn; Dr. Lu Lu, 86-21-54237671, Email: lul@fudan.edu.cn; 26
- or Dr. Tongyu Zhu, 86-21-37990333, Email: zhutongyu@shphc.org.cn. 27
- **Keywords**: COVID-19; SARS-CoV-2; ADE; Neutralizing antibody 29

Abstract

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 59

Antibody-dependent enhancement (ADE) has been reported in several virus infections including dengue fever virus, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronavirus infection. To study whether ADE is involved in COVID-19 infections, in vitro pseudotyped SARS-CoV-2 entry into Raji cells, K562 cells, and primary B cells mediated by plasma from recovered COVID-19 patients were employed as models. The enhancement of SARS-CoV-2 entry into cells was more commonly detected in plasma from severely-affected elderly patients with high titers of SARS-CoV-2 spike protein-specific antibodies. Cellular entry was mediated via the engagement of FcyRII receptor through virus-cell membrane fusion, but not by endocytosis. Peptide array scanning analyses showed that antibodies which promote SARS-CoV-2 infection targeted the variable regions of the RBD domain. To further characterize the association between the spike-specific antibody and ADE, an RBD-specific monoclonal antibody (7F3) was isolated from a recovered patient, which potently inhibited SARS-Cov-2 infection of ACE-2 expressing cells and also mediated ADE in Raji cells. Site-directed mutagenesis the spike RBD domain reduced the neutralization activity of 7F3, but did not abolish its binding to the RBD domain. Structural analysis using cryo-electron microscopy (Cryo-EM) revealed that 7F3 binds to spike proteins at a shift-angled pattern with one "up" and two "down" RBDs, resulting in partial overlapping with the receptor binding motif (RBM), while a neutralizing monoclonal antibody that lacked ADE activity binds to spike proteins with three "up" RBDs, resulting in complete overlapping with RBM. Our results revealed that ADE mediated by SARS-CoV-2 spike-specific antibodies could result from binding to the receptor in slightly different pattern from antibodies mediating neutralizations. Studies on ADE using antibodies from recovered patients via cell biology and structural biology technology could be of use for developing novel therapeutic and preventive measures for control of COVID-19 infection.

Introduction

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

The global pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had resulted in a total of 34.8 million cases of infection and over 1 million deaths worldwide by October 4, 2020, 1. No therapeutic drugs against SARS-CoV-2 are currently available, and the development of vaccines is considered as the most effective approach to control the ongoing pandemic. Multiple platforms are being developed as a SARS-CoV-2 vaccine, including DNA- and RNA-based formulations, recombinant viral subunits, replicating viral vectors and purified inactivated viral particles, are under development, and several vaccine candidates are presently being evaluated for efficacy in phase III trials². Most vaccines incorporate SARS-CoV-2 spike (S) protein or its receptor-binding domain (RBD) as immunogens. As the primary targets for neutralizing antibodies (NAbs), the S protein and RBD are promising immunogens to induce protective NAbs in vaccine recipients³⁻⁶. However, preclinical experience with severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) vaccine candidates has raised safety concerns about the potential for antibody-dependent enhancement (ADE) induced by coronavirus S protein⁷⁻¹¹. ADE is an enhancement of viral entry into immune cells mediated by antibody via the engagement of the Fc receptors 12,13. This phenomenon has been documented with mosquito-borne flavivirus infections, such as dengue¹⁴ and Zika viruses¹⁵. For dengue virus, the ADE of virus infection of immune cells resulted in the enhancement of disease severity especially at the second infections with different virus strains in humans¹⁶. For coronaviruses, ADE has been mainly reported in animal models infected by SARS-CoV, MERS-CoV and feline coronavirus, in which exacerbated lung disease was observed when vaccinated animals were infected with viruses^{7,10,17}. In both SARS-CoV and MERS-CoV infections, ADE was mediated with antibodies against spike (S) proteins^{7,9}. Although S protein-specific antibodies were elicited in most patients with COVID-19, the antibody titers were higher in elderly patients of COVID-19, and stronger antibody response was associated with delayed viral clearance and increased disease severity in patients 18,19. Hence it is reasonable to

speculate that S protein-specific antibodies may contribute to disease severity during SARS-CoV-2 infection^{11,20,21}. Furthermore, the potential for such ADE responses is of concern for SARS-CoV-2 in the use of convalescent plasma or antibodies as a treatment in COVID-19 patients ^{22,23}. However, whether SARS-CoV-2 specific antibodies or convalescent plasma could promote virus infection of immune cells or enhance disease severity has not been documented. Here, we used an in vitro pseudotyped SARS-CoV-2 infection assay to evaluate the ability of plasma and antibodies from recovered COVID-19 patients to promote SARS-CoV-2 infection of immune cells, and analyzed the associated clinical and immunological characteristics. **Results Clinical Characteristics** This study enrolled 222 patients in total who had recovered from COVID-19 and were discharged from the Shanghai Public Health Clinical Center as of April 23, 2020. Of the 222 patients, 205 had mild symptoms and 17 had severe symptoms. The median [interquartile range, IQR] age of patients was 53 [38-65] years; 49 % of the patients were female. The median length of hospital stay was 17 [13-24] days, and the median disease duration was 23 [18-30] days. Plasma from recovered patients of COVID-19 showed enhancement of SARS-CoV-2 infection of immune cells We collected plasma samples from 205 patients who had recovered from mild COVID-19 at the time of discharge (median days 22), as well as 17 patients who had recovered from severe COVID-19 at the time before discharge (median days 34), and evaluated the enhancement of pseudotyped SARS-CoV-2 infection in vitro for each patient plasma by using Raji cells that are lymphoma cells derived from human B lymphocytes. The cells expressed human FcyRII (CD32) and were used for ADE assay of SARS-CoV

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

previously²⁴. Plasma from 16 (8%) of the recovered patients with mild COVID-19 and 13 (76%) of the recovered patients with severe COVID-19 (N=17, median age 66) showed a concentration-dependent enhancement of SARS-CoV-2 infection of Raji cells, indicated by the increase of luciferase expression in Raji cells (Figure S1,1A). The enhancement of virus infection was significantly higher in plasma from COVID-19 patients compared with plasma from uninfected controls (P < 0.0001, Figure 1B, S1). Moreover, plasma from these 29 patients also showed detectable enhanced infection of Raji cells of pseudotyped bat-origin SARS-like coronavirus, either RS3367 or WIV1 (P = 0.0108 or P = 0.0046, Figure 1B), while none of the plasma showed enhancement of SARS-CoV infection (Figure 1B). The enhancement of SARS-CoV-2 infection by patient plasma was also observed when K562 cells derived from human monocytes were used as targets (P = 0.0006, Figure S2, 1C). Furthermore, the enhancement of SARS-CoV-2 infection was also confirmed when cultured primary B cells were used as targets. As shown in Figure S3, eight representative positive plasma samples, four from patients with mild COVID-19 and the other four from patients with severe COVID-19, showed concentration-dependent enhancement of SARS-CoV-2 infection of primary B cells. These eight plasma mediated significantly higher SARS-CoV-2 infection than control plasma from uninfected donors (P = 0.004, Figure 1D). In the following studies, Raji cells were used as targets on the mechanism of enhancement of SARS-CoV2 infection because they were easily maintained and generated higher luciferase reading than K562 cells and primary B cells. Enhancement of SARS-CoV-2 infection was mediated by IgG antibodies engagement of FcyRII receptor To confirm whether the enhancement of SARS-CoV-2 infection was mediated by antibodies, we purified IgG from the plasma and measured the enhancement of SARS-CoV-2 infection of Raji cells by purified antibodies and IgG-depleted plasma,

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

respectively. As shown in Figure 1E, purified IgG showed enhancement of SARS-CoV-2 infection, which was similar to plasma from patients. The depletion of IgG from plasma completely abolished the infection of Raji cells, confirming that the enhancement of SARS-CoV-2 infection was mediated by IgG in plasma. We further used anti-CD32 antibody to block the cell surface FcxRII receptor to evaluate the engagement of FcxRII receptor in promoting SARS-CoV-2 infection. The addition of anti-CD32 antibody eliminated the enhancement of SARS-CoV-2 infection by both plasma (Figure 1F) and purified IgG (Figure 1G) from patients. These results indicated that the *in vitro* enhancement of SARS-CoV-2 infection by patient plasma was mediated by IgG antibodies with the engagement of FcxRII receptor, which is similar to the ADE of virus infections including SARS-CoV, MERS-CoV, Zika, and dengue viruses.

ADE is more likely to develop in elderly patients with severe and critical condition,

longer hospital stays and disease duration

We investigated the clinical characteristics of 29 recovered patients whose plasma showed ADE effect. The median age of these patients (65 [58-72] years) was significantly higher than the patients without ADE effect (50 [37-64] years, P < 0.0001, Figure 1H). The median disease duration time and the length of hospital stays of patients whose plasma showed ADE was significantly longer than patients without ADE effect (35 [23-60] days *vs.* 22 [18-29] days, P < 0.0001, and 30 [19-55] days *vs.* 17 [13-23] days, P < 0.0001, Figure 1I and 1J). These results indicated that ADE is more likely to develop in elderly patients with severe and critical condition, longer hospital stays and disease duration, suggesting a possible association of ADE with disease severity in COVID-19 patients.

To evaluate whether the ADE effect resulted from pre-exposure to other pathogens in elderly patients, we collected plasma from 18 uninfected elderly donors aged 60 to 80 years and tested them for ADE. None of the plasma from uninfected control donors showed an ADE effect (P = 0.3085, Figure S4), confirming that ADE appeared to be

the result of SARS-CoV-2 infection.

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

ADE is more likely to develop in patients with high titers of SARS-CoV-2 RBDand S1-specific antibodies Next, we evaluated the relationship between ADE effect and SARS-CoV-2-specific antibodies. Significantly higher titers of SARS-CoV-2 NAbs (P < 0.0001, Figure 2A), as well as RBD-specific (P < 0.0001) and S1-specific binding antibodies (P < 0.0001) (Figure 2B), were found in plasma with ADE effect compared to plasma without ADE effect, while S2-specific antibodies showed no difference. Then we evaluated the kinetics of ADE effect, binding antibodies, and NAbs during the course of disease in six patients for whom sequential plasma samples were available. The kinetics of ADE development was similar among all patients, starting to increase at day 10 post-disease onset, reaching their peak at day 20, and remaining stable for at least 40-81 days (Figure 2C and Figure S5A). The kinetics of titers of antibodies binding to RBD and S1 (Figure 2D and Figure S5B) was similar to the kinetics of ADE (Figure 2C and Figure S5B red line), while the kinetics of NAbs in these patients was different. The titers of NAbs in the six patients increased on day 10 post-disease onset and reached a very high level around day 20 (median ID50 = 2877) (Figure 2E and Figure S3C blue line). However, NAb titers dramatically dropped to low levels (median ID50 = 545) after day 30 postdisease onset. These results indicated that high levels of binding antibodies might contribute to the ADE of SARS-CoV-2 infection. ADE was mediated by antibodies binding to SARS-CoV-2 spike RBD subunits To further determine the role of spike-specific antibodies in mediating ADE of SARS-CoV-2 infection, we incubated SARS-CoV-2 RBD and S1 proteins with plasma to block the protein-specific antibodies before measuring the ADE effect of plasma samples. Pre-incubation with SARS-CoV-2 RBD protein at a concentration as low as 0.1 µg/ml

could completely block the ADE effect of plasma from the representative patient 8

(Figure 3A), and pre-incubation with S1 protein at the concentration of 1 μ g/ml could also block the ADE effect (Figure 3B). However, pre-incubation with SARS-CoV RBD or S1 protein did not change the ADE activity in plasma (Figure 3C and 3D). The inhibition of ADE effect by SARS-CoV-2 RBD protein was also observed in the plasma from other patients. As shown in Figure 3E, pre-incubation of 10 μ g/ml SARS-CoV-2 RBD significantly reduced ADE effect mediated by plasma from six tested patients (P = 0.009). These results indicated that the ADE of SARS-CoV-2 infection was mediated by antibodies targeting SARS-CoV-2 spike RBD subunits.

ADE of SARS-CoV-2 infection occurred through the virus-cell membrane fusion

It was suggested that the ADE of viral infection was mediated by phagocytosis of immune complexes via Fc γ RII / CD32 receptor²⁵. However, the addition of chloroquine, a phagocytosis inhibitor which could raise the pH of phagolysosomes and inhibit the phagocytosis of mononuclear cells²⁶, did not inhibit the ADE by the plasma, even at the highest concentration of 50 μ M (Figure 4A). In contrast, EK1 peptide, which has been demonstrated to inhibit virus-cell membranes fusion by binding to the HR1 domain and thus inhibiting the formation of the six-helix bundle (6HB) of SARS-CoV-2 S2 protein²⁷, blocked ADE of SARS-CoV-2 infection in a dose-dependent manner (Figure 4B). The inhibition of ADE effect by EK1 peptide, but not chloroquine, was observed for six tested plasma samples with ADE effect (P = 0.0064, Figure 4C). These results indicated that ADE of SARS-CoV-2 infection was mediated through virus-to-cell membrane fusion, not phagocytosis.

The ability of plasma to promote virus-to-cell membrane fusion was confirmed by an *in vitro* syncytium formation assay, using HEK-293T cells expressing the SARS-CoV-2 S protein as effector cells and Raji cells as target cells. No syncytium formation occurred in the presence of control plasma (Figure 4D, left). However, large syncytium was induced by plasma from representative patients 5, 7, and 8 in a dose-dependent manner (Figure 4D, middle; Figure 4E). The syncytium formation induced by plasma

from COVID-19 patients was specifically inhibited by the addition of EK1 peptide, but not chloroquine (Figure 4D, right; Figure 4E). These results again confirmed that ADE of SARS-CoV-2 infection by plasma was mainly through cell-to-cell membrane fusion, a pathway involved in the formation of the six-helix bundle (6HB) of SARS-CoV-2 S2 protein, which could be inhibited by EK1 peptide.

RBD-specific human NAb 7F3 with ADE effect enhanced SARS-CoV-2 infection and promoted virus entry into Raji cells through the virus-cell membrane fusion We further evaluated the characterization of antibodies with ADE effect by isolating two monoclonal antibodies (mAbs) from recovered COVID-19 patient. These two mAbs, termed as 7F3 and 4L12, were isolated by in vitro single B cell culture and subsequent high-throughput micro-neutralization screening assay from the same recovered COVID-19 patient. Both of the antibodies potently neutralized SARS-CoV-2 pesudovirus infection of 293T cells expressing ACE2 protein with an IC50 of 0.00684 μg/ml and 0.00452 μg/ml, respectively (Figure 5A). The two antibodies bound to SARS-CoV-2 RBD and S1 proteins, but not S2, in the ELISA assay (Figure 5B). Antibody 7F3 had higher binding affinity to RBD protein with a KD value of 0.69± 0.03 nM, when compared to antibody 4L12 which bound to RBD with a KD value of 1.49 ± 0.06 nM (Figure 5C). Antibody 7F3 showed a concentration-dependent enhancement of SARS-CoV-2 infection of Raji cells (Figure 5D), while antibody 4L12 did not. The enhancement of SARS-CoV-2 infection by antibody 7F3 was also dependent on the interaction between antibody Fc region with FcxRII receptor, because the enhancement could be completely abolished by either removal of antibody Fc region (Figure 5E) or blocking FcxRII receptor with anti-CD32 antibody (Figure 5F). We also compared the ADE effect of different isotypes of 7F3 antibodies which were generated by linking different heavy-chain constant regions to the same variable region of 7F3 antibody. The IgG1 isotype showed the strongest ADE effect, IgG4 isotype showed detectable ADE effect, while IgG2 and IgG3 did not show any detectable ADE

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

(Figure 5G), possibly resulting from the different binding affinity to FcxRII receptor on Raji cells. Consistent with the observations for plasma samples from recovered patients, antibody 7F3-mediated enhancement of SARS-CoV-2 infection could be specifically reduced by pre-incubation with RBD protein of SARS-CoV-2, but not from SARS-CoV virus (Figure 5H), and the ADE could also be blocked by fusion-inhibitor EK1 peptide, but not chloroquine (Figure 5I), suggesting that antibody 7F3-mediated ADE of SARS-CoV-2 infection of Raji cells also occurred through virus-to-cell membrane fusion. Peptide scanning for hot spots in RBD associated with ADE effect Next, we explored the epitopes in RBD to which patient plasma and NAb 7F3 bound and induced ADE. We synthesized a series of 20-mer peptides with 10 amino acid overlap spanning the RBD region (304-593) to block the ADE of patient plasma and antibody 7F3. Peptides from the S1 region, i.e., 304-323, 364-383, 544-563, 564-583, and 574-593, dramatically blocked the ADE of both patient plasma (Figure 6A) and 7F3 (Figure 6B) and decreased >70 % of AUC (Figure 6C). Peptides from S1 regions 454-473 and 484-503 decreased 50-62% of the AUC for both ADE patient plasma and 7F3. Peptides from S1 regions 484-403 and 525-543 specifically blocked ADE patient plasma, but not 7F3. These results suggested that several epitopes in RBD were associated with ADE by antibodies. ADE antibody 7F3 and non-ADE antibody 4L12 shared overlapping epitopes but showed different binding abilities to RBD To more precisely map the epitopes on RBD recognized by antibody 7F3, we introduced single amino acid substitutions into the spike RBD domain and constructed 25 spike mutants, including seven mutants that were reported to be resistant to NAbs²⁸, as well as a prevalent mutant D614G²⁹ (Figure 7, highlighted in blue), and evaluated their sensitivity to neutralization of antibody 7F3. As shown in Figure 7A, 7F3 neutralized all seven mutants that resistant to NAbs and the prevalent mutant D614D.

Three amino acid substitutions, including F342L, P491A, and E516A exhibited

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

complete resistance to the neutralization of both 7F3 and 4L12 (IC50 >50 µg/ml), suggesting overlapping between the epitopes of 7F3 and 4L12. We expressed the RBD protein mutants and measured the binding ability of 7F3 to these mutants relative to wild type RBD. None of these mutations except P491A affected 7F3 and 4L12 binding to spike protein (Figure 7B and 7C). A mutant with single mutation D427A and four mutants with three amino acid alanine substitutions in RBD showed decreased binding to 4L12 but had no effect on 7F3 binding (Figure 7B and 7C). Even though mutations F342L and E516A in the RBD region affected 7F3 neutralization, they did not impact 7F3 binding, which may play an important role in ADE. Structures of 7F3 or 4L12 in complex with the S protein of SARS-CoV-2 revealed different binding patterns To characterize the molecular details of the antibodies mediating ADE, we solved the cryo-EM structures of S-ECD bound with 7F3 or 4L12 at an overall resolution of 3.3 Å and 3.0 Å, respectively (Figure S6-S8, Table S1). Details of cryo-EM sample preparation, data collection and processing, as well as model building, can be found in the Materials and Methods section in Supplementary Information (SI). The overall resolution for S-ECD was good enough for model building, whereas the resolution at the interface between 7F3 and S-ECD was worse owing to the flexibility. We only docked the light chain and heavy chain of 7F3 into the cryo EM map. The S protein bound with 7F3 exhibits a conformation with one "up" and two "down" RBDs, among which the "up" RBD and one of two "down" RBDs were bound by 7F3, whereas the other "down" RBD was not bound by 7F3 (Figure 8A). In contrast to the S/7F3 complex, all three RBDs of S protein were in "up" conformation and bound with 4L12 in the S/4L12 complex (Figure 8B). Additionally, the interfaces between antibodies and RBD in both antibodies are overlapped with binding to ACE2 (Figure S9). The resolution at the interface between 4L12 and RBD was improved to 3.5 Å by

focused refinement, allowing detailed analysis (Fig. S7). When compared with 4L12

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

bound structure, 7F3 bound to RBD with a shift of about 28.5 angstroms (Figure 8C), making a different binding pattern. In summary, structural analysis indicates that both 7F3 and 4L12 can block the binding between ACE2 and RBD. The binding interface of 7F3 is accessible on the "down" RBD and is partially overlapped with the edge of the receptor binding motif (RBM) (Figure 8D), which is consistent with the competing results of peptides 454-473 and 484-503 (Figure 6C) and the amino acid P491A substitution result (Figure 7A, B). Additionally, the epitope residues of 4L12 are distributed across RBM, fully competing with ACE2 (Figure 8D). These results suggest that the different ability of antibody 7F3 and 4L12 to induce ADE may result from the different binding patterns to spike proteins.

Discussion

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

The role of antibodies during SARS-CoV-2 infection has remained unclear. For most infectious viral diseases, the concentrations of virus-specific antibodies correlate with viral clearance and protection, while it is different in patients of COVID-19. It was reported that stronger antibody response was associated with delayed viral clearance and increased disease severity in patients of COVID-19³⁰. We also reported that NAb titers were higher in elderly patients of COVID-19, who tend to have worse outcomes, while a few patients recovered without generating detectable NAbs¹⁸. Here we reported the observation of in vitro ADE of SARS-CoV-2 entry into FcvRII receptor-bearing cells by plasma and antibodies from patients who recovered from COVID-19. The antibody enhancement of SARS-CoV-2 entry may enhance viral replication in immune cells, since it has been reported that SARS-CoV-2 could productively infect immune cells including monocytes and B cells both in vivo and ex vivo³¹. Because of the limited availability of tissue samples from these patients, we could not directly evaluate the immuno-pathological damage associated with ADE. However, in our study the enhancement of virus infection was more commonly observed in plasma from older patients with severe symptoms, and it was associated with prolonged disease duration,

suggesting that ADE may be associated with worse clinical outcomes during SARS-CoV-2 infection. Previous studies on SARS-CoV have shown that antibodies mediating ADE of SARS-CoV infection were mainly targeting an immunodominant linear epitope (S597–603) located at C-terminal domain of SARS-CoV spike protein³². Here we found that antibodies mediating enhancement of SARS-CoV-2 infection were mainly targeting the RBD domain of SARS-CoV-2 spike protein. The enhancement could be completely blocked by pre-adsorption of RBD-specific antibodies in plasma with RBD protein. As the receptor binding site of the spike protein, the RBD domain is the main target for neutralizing antibodies³³. Our results indicated that some RBD-specific antibodies, for example antibody 7F3 in this study, have dual effects in mediating both neutralization and ADE. The effect of neutralization or ADE was dependent on receptor expression on the target cells and concentration of the antibody. When viruses infect cells expressing ACE2, such as Huh-7 cells or lung alveolar epithelial cells, antibody 7F3 at optimal neutralizing concentration could block RBD binding to ACE2 and inhibit viral infection. However, when viruses infect cells expressing Fc receptors, such as Raji, K562, or primary immune cells, the antibody at suboptimal neutralizing concentration promotes virus entry into cells through interaction between antibody and Fc receptors (Figure 9). We found that amino acid substitutions F342L and E516A on RBD allowed the virus escape from the neutralization by 7F3 without reducing binding affinity to antibody. How these mutants abolished the antibody neutralization without affecting binding affinity requires further studies. It is interesting that antibody-mediated viral entry into Fc receptor-bearing cells was not through phagocytosis, but rather, through virus-to-cell membrane fusion. However, the molecular mechanism that regulates the interaction among spike protein, antibody and Fc receptors in order to initiate virus-cell membrane fusion remains unknown. It should be noted that not all RBD-specific antibodies will induce ADE effect. Antibodies that can induce ADE in this study bind to the spike with one "up" and two "down" RBD domains, while the antibodies that cannot induce ADE bind to the spike with three "up"

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

RBD domains. Therefore, the different binding pattern to spike proteins may result in different abilities to promote ADE, but the detailed mechanism requires further studies. Our results revealed that antibodies mediating ADE of SARS-CoV-2 infection were not the result of pre-existing cross-reactive antibodies from other coronavirus infection³⁴, but were generated *de novo* following infection with SARS-CoV-2. First, the plasma from COVID-19 patients did not significantly promote the enhancement of SARS-CoV coronavirus infection. Second, pre-incubation with SARS-CoV RBD did not block the enhancement of virus infection by either plasma or monoclonal antibody 7F3. Third, mAb 7F3, which promotes the enhancement of virus infection, specifically binds to RBD of SARS-COV-2 virus, but no other coronaviruses. These results also suggest that ADE may be more likely to occur at later time points after recovery from COVID-19

when the concentration of neutralizing antibodies elicited by the primary SARS-CoV-

Limitations

In this study, plasma and antibodies was measured by an *in vitro* cell-based pseudovirus assay to evaluate the enhancement of SARS-CoV-2 infection of immune cells. Whether such enhancement of virus infection results in disease severity needs to be validated in appropriate animal models.

Implication for SARS-CoV-2 vaccine research and therapies

2 infection have waned to suboptimal neutralizing level.

Although several SARS-Cov-2 vaccines have been undergoing phase III clinical trials, the potential ADE of coronavirus infection still remains a safety concern for any vaccine candidates. The observation of enhancement of SARS-CoV-2 infection mediated by plasma and antibodies from recovered COVID-19 patients in this study does not indicate that vaccine candidates would necessarily induce ADE or disease severity. However, these results suggest that vaccine candidates should be evaluated for

induced in addition to induction of neutralizing antibodies. A vaccine that can induce high titers of neutralizing antibodies should be safer than one inducing low titers since 1) most the newly invaded virions are neutralized before the ADE occurs and 2) neutralizing antibodies mediate ADE only at the suboptimal neutralizing concentration. Furthermore, these results also suggested that plasma and antibodies from patients who recovered from COVID-19 should be tested for potential ADE effect before clinical usage.

Methods

Study design and participants

The study was conducted under a clinical protocol approved by the Investigational Review Board in the Shanghai Public Health Clinical Center (Study number: YJ-2020-S018-02). The study included a cohort of 222 adult COVID-19 recovered patients who were quarantined and hospitalized at the Shanghai Public Health Clinical Center. All patients were diagnosed with laboratory-confirmed SARS-CoV-2 infection by positive results of reverse transcriptase—polymerase chain reaction (RT-PCR) testing of nasopharyngeal samples. 205 patients were categorized as mild symptoms, and 17 patients were in severe and critical condition according to the Guidelines on the Diagnosis and Treatment of Novel Coronavirus issued by the National Health Commission, China. All participants signed an informed consent approved by the IRB. All patients had recovered and were discharged after meeting effective national treatment standards.

Materials

The human primary embryonic kidney cell line (HEK293T) (CRL-3216TM) and Raji cells were obtained from the American Type Culture Collection (ATCC). 293T cells expressing human angiotensin converting enzyme II (ACE2) (293 T/ACE2) were

constructed as previously described¹⁸. CD19+IgA-IgD-IgM- Primary B cells were sorted out from peripheral blood mononuclear cell (PBMC) of recovered patients of COVID-19 and expanded in vitro for 13 days in the presence of irritated 3T3-msCD40L feeder cells, IL-2 and IL-21 as previously described³⁵. Raji cells and K562 cells were cultured in RPMI 1640 medium with 10% fetal bovine serum (FBS), and the other cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) with 10% FBS. HEK293 cells expressing SARS-CoV-2 RBD protein was purchased from GenScript Company (Nanjing, China). SARS-CoV-2 S1 and S2 proteins, as well as SARS-CoV S1 and RBD proteins were purchased from Sino Biological Company (Beijing, China). The 20-mer peptides with 10 amino acid overlap spanning the entire RBD region and EK1 (SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL) peptide were synthesized by Jetide (Wuhan, China). The expression plasmids for SARS S protein, pcDNA3.1-SARS-S (GenBank accession: ABD72979.1), SARS-CoV-2 S protein, pcDNA3.1-SARS-CoV-2-S (GenBank accession: NC 045512), and pcDNA3.1-RS3367 (GenBank accession: KC881006) were synthesized by Genscript. The HIV-1 Env-deficient luciferase reporter vector pNL4-3. Luc. R-E- and 3T3mCD40L cells were obtained through the NIH AIDS Reagent Program. Chloroquine was purchased from TargetMol. Pseudoviruses of SARS-CoV-2, SARS-CoV, Bat-SL-RS3367 and WIV1 coronaviruses were generated by cotransfection of 293T cells with pNL4-3.Luc.R-Ebackbone and viral envelope protein expression plasmids as previously described¹⁸. Mouse anti-human CD32 monoclonal antibody (clone number FLI8.26) was purchased from BD Pharmingen (USA). ADE of pseudotyped SARS-CoV-2 infection of Raji cells, K562 cells, and primary

B cells

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

- The ADE effect of plasma and antibodies was measured by in vitro enhancement of 450
- pseudotyped SARS-CoV-2 infection with Raji cells, K562 cells and primary B cells. 451
- 452 Briefly, 50 µl of Raji cells or K562 cells were seeded into a 96-well plate pre-coated

with 100 µl of 0.1 mg/ml Poly L-lysine at a concentration of 2 X 10⁴ cells per well and cultured at 37 °C for 48 hours. For primary B cells ADE assay, 100 µl of cultured B cells were seeded into wells at a concentration of 1 X 10⁴ cells per well in the presence of irritated 3T3-msCD40L feeder cells, IL-2, and IL-21 and cultured at 37 °C for 48 hours. Ten µl of heat-inactivated plasma were two-fold serially diluted with DMEM with 10% FBS and mixed with 40 µl pseudovirus at 37 °C for 30 minutes. For ADE inhibition assay, different concentrations of RBD or S1 protein from SARS-CoV-2, RBD or S1 protein from SARS-CoV, 20-mer peptides spanning RBD region (20 µg/ml), EK1 peptide (50 μM), or chloroquine (50 μM), or mouse anti-human CD32 monoclonal antibody (5 µg/ml) were incubated with serially diluted patient plasma at 37 °C for 1 hour before mixing with pseudovirus. The mixture was added into cultured cells for infection. After 12 hours, 150 µl of culture medium were added to the cells and incubated for an additional 48 hours. The infection of cells was evaluated by luciferase expression, as determined with a luciferase assay system (Promega) and read on a luminometer (Perkin Elmer). The enhancement of virus infection was expressed as the fold changes of luciferase reading comparing to virus control without addition of plasma or antibodies.

Purification of IgG from human plasma

Heat-inactivated human plasma samples were 1:6 diluted in PBS and filtered through 0.22 μm filters. The diluted plasma was incubated with protein G beads (Smart-Lifesciences) at 4 °C overnight. The mixture was loaded on filtration column, and IgG-depleted plasma was collected from the flow through. After washing with 150 ml PBS, the beads binding IgG were eluted with 8 ml of 0.1M glycine-HCl buffer (pH 2.7) and neutralized with 200 μ l of 2 M Tris-HCl buffer (pH 8.0). The eluted IgG was concentrated using Amicon Ultra centrifugation units (50 kDa, Millipore) after triple washing with 15 ml PBS. Purified IgG was diluted with PBS to the same volume as that of the original plasma samples before evaluation.

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

Neutralization assay

Neutralization activity of plasma and antibodies was measured by the inhibition of pseudovirus infection with 293 T/ACE2 cells as previously described¹⁸. Briefly, 293 T/ACE2 cells were seeded in a 96-well plate at a concentration of 10⁴ cells per well and cultured for 12 hours. Then, ten μl heat-inactivated plasma were five-fold serially diluted with DMEM with 10% FBS and mixed with 40 μl of pseudovirus. The mixture was added to cultured 293 T/ACE2 cells for infection. The culture medium was refreshed after 12 hours and incubated for an additional 48 hours. Assays were developed with a luciferase assay system (Promega), and the relative light units (RLU) were read on a luminometer (Perkin Elmer). The titers of NAbs were calculated as 50% inhibitory dose (ID50), expressed as the highest dilution of plasma which resulted in a 50% reduction of luciferase luminescence compared with virus control.

Cell-cell fusion assay mediated by ADE patient plasma.

Cell-cell fusion assay was conducted as previously described with modification²⁷. Briefly, HEK-293T cells expressing the SARS-CoV-2 S protein on the cell membrane were used as effector cells, while Raji cells were used as target cells. HEK293T cells were transfected with plasmid pAAV-IRES-EGFP-SARS-2-S, using transfection reagent VigoFect (Vigorous Biotechnology, China). Raji cells were seeded at a density of 5 x 10⁴ cells per well into the 96-well plates which were precoated with 100 μl of 0.1 mg/ml of Poly L-lysine for 30 min at 37°C. The effector cells were collected 24 hours after transfection and mixed with the serially diluted serum at 37°C for 30 min. The mixture of effector cells and serum was applied onto the Raji cells and cultured for an additional 24 hours. After fixing with 4 % paraformaldehyde, the cells were observed and captured using an inverted fluorescence microscope (Nikon Eclipse Ti-S). The fused cells were counted on five random fields in each well. For inhibition assay, EK1 peptide or chloroquine (TargetMol) was two-fold serially diluted in RPMI 1640 and

then mixed with the effector cells and serially diluted ADE patient plasma at 37°C for 30 min. Then, the mixture was applied to the Raji cell as described above.

ELISA

SARS-CoV-2 RBD, S1, or S2 protein were coated on a MaxiSorp Nunc-immuno 96-well plate (Thermo Scientific, USA) overnight at 4 °C. Wells were blocked with 5% nonfat milk (Biofroxx, Germany) in PBS for 1 hour at room temperature, followed by incubation with 1:400 diluted sera or serially diluted sera in disruption buffer (PBS, 5% FBS, 2% BSA, and 1% Tween-20) for 1 hour at room temperature. A 1:2500 dilution of horseradish peroxidase (HRP)-conjugated goat anti-human IgG antibody (Jackson Immuno Research Laboratories, USA) was added for 1 hour at room temperature. Wells were developed using ABST (Thermo Scientific, USA) for 30 minutes and read at 405 nm on a Multiskan FC plate reader (Thermo Scientific, USA).

Memory B-cell staining, sorting and antibody cloning

SARS-CoV-2-specific monoclonal antibodies were isolated from mononuclear cells (PBMC) of recovered patients by *in vitro* single B cell as previously described³⁵. Briefly, CD19⁺IgA⁻IgD⁻IgM⁻ memory B cells were sorted and resuspended in medium with IL-2, IL-21, and irradiated 3T3-msCD40L feeder cells, followed by seeding into 384-well plates at a density of 4 cells per well. After 13 days of incubation, supernatants from each well were screened for neutralization activity using a high-throughput microneutralization assay against SARS-CoV-2. From the wells that scored positive in the neutralization assay, the variable region of the heavy chain and the light chain of the immunoglobulin gene was amplified by RT–PCR and re-expressed as described previously^{36,37}. The full-length IgG was purified using a protein G column (Smart-Lifesciences).

Biolayer interferometry binding assay

The kinetics of monoclonal antibody binding to SARS-CoV-2 RBD protein was measured by biolayer interferometry binding assay on a FortéBio OctetRED96 instrument using anti-human IgG (AHC) biosensors as previously described The assay followed sequential steps at 30°C as follows. First, the biosensor was immersed in sterile water for 60s, and 10 μ g/ml of antibody was loaded on the biosensors. The biosensors were dipped into 0.02% PBST (PBS with 0.02% Tween) for 300 s to reach baseline and then incubated with serially diluted RBD protein solutions for association and PBST for dissociation. Results were analyzed, and K_{on} , K_{off} and KD were calculated by FortéBio Data Analysis software (Version 8.1) using 1:1 binding and a global fitting model.

Cryo-EM sample preparation

The peak fractions of complex were concentrated to about 1.5 mg/mL and applied to the grids. Aliquots (3.3 μ L) of the protein complex were placed on glow-discharged holey carbon grids (Quantifoil Au R1.2/1.3). The grids were blotted for 2.5 s or 3.0 s and flash-frozen in liquid ethane cooled by liquid nitrogen with Vitrobot (Mark IV, Thermo Scientific). The cryo-EM samples were transferred to a Titan Krios operating at 300 kV equipped with Cs corrector, Gatan K3 Summit detector and GIF Quantum energy filter. Movie stacks were automatically collected using AutoEMation ³⁹, with a slit width of 20 eV on the energy filter and a defocus range from -1.2 μ m to -2.2 μ m in super-resolution mode at a nominal magnification of 81,000×. Each stack was exposed for 2.56 s with an exposure time of 0.08 s per frame, resulting in a total of 32 frames per stack. The total dose rate was approximately 50 e⁻/Å² for each stack. The stacks were motion corrected with MotionCor2 ⁴⁰ and binned 2-fold, resulting in a pixel size of 1.087 Å/pixel. Meanwhile, dose weighting was performed ⁴¹. The defocus values were estimated with Gctf ⁴².

Data processing

Particles for all samples were automatically picked using Relion 3.0.6⁴³⁻⁴⁶ from

manually selected micrographs. After 2D classification with Relion, good particles were selected and subjected to two cycles of heterogeneous refinement without symmetry using cryoSPARC ⁴⁷. The good particles were selected and subjected to Nonuniform Refinement (beta) with C1 symmetry, resulting in 3D reconstruction for the whole structures, which were further subjected to 3D auto-refinement and postprocessing with Relion. For interface between SARS-CoV-2 S protein and mAb, the dataset was subjected to focused refinement with adapted mask on each RBD-mAb subcomplex to improve map quality. Then the datasets of three similar RBD-mAb subcomplexes were combined and subjected to focused refinement with Relion. The combined dataset was recentered on the interface between RBD and mAb and reextracted. The re-extracted dataset was 3D classified with Relion focused on RBD-mAb sub-complex. Then the good particles were selected and subjected to focused refinement with Relion, resulting in 3D reconstruction of better quality on the RBDmAb sub-complex. The resolution was estimated with the gold-standard Fourier shell correlation 0.143 criterion ⁴⁸ with high-resolution noise substitution ⁴⁹. Refer to Supplemental Figures S6-S7 and Supplemental Table S1 for details of data collection and processing.

Model building and structure refinement

For model building of all complexes of S-ECD of SARS-CoV-2 with mAb, atomic models (PDB ID: 7C2L) were used as templates, which were molecular dynamics flexible fitted ⁵⁰ into the whole cryo-EM map of the complex and the focused-refined cryo-EM map of the RBD-mAb sub-complex, respectively. The fitted atomic models were further manually adjusted with Coot ⁵¹. Each residue was manually checked with the chemical properties taken into consideration during model building. Several segments were not modeled because the corresponding densities were invisible. Structural refinement was performed in Phenix⁵² with secondary structure and geometry restraints to prevent overfitting. To monitor the potential overfitting, the model was refined against one of the two independent half maps from the gold standard

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

3D refinement approach. Then, the refined model was tested against the other maps. Statistics associated with data collection, 3D reconstruction, and model building were summarized in Table S1. Statistical analysis Statistical analyses were carried out using GraphPad Prism 7.0. Data are indicated as median [IQR]. Differences between nominal data were tested for statistical significance by use of Nonparametric paired or unpaired t test. Kruskal-Wallis test was used to compare the differences between three or more groups, and Dunn's multiple comparisons test was used to correct for multiple comparisons. All tests were two-tailed, and P < .05 was considered statistically significant. Role of the funding source The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all data in the study and had final responsibility for the decision to submit for publication. **Declaration of interests** Patents about the monoclonal antibodies 7F3 and 4L12 in this study are pending. **Contributions** JH, FW, QZ, LL conceived and designed the experiments. ZS, YZ, and TZ collected the samples and clinical information of patients. JH, ML and FW performed ADE experiments, blocking experiments, peptide array, neutralization assay, ELISA, memory B-cell staining, sorting, and antibody cloning. RY, QZ, ZY and LY performed the structural studies. ZL and LL performed cell-cell fusion assay and blocking assay. YDW, TS, XL, ZL, CL, and TY constructed and expressed SARS-CoV-2 pseudovirus mutants and RBD-Fc protein mutants. YDW, YLW, and JH performed biolayer

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

- interferometry binding assay. YDW and YM performed ELISA. DL and YM 622
- contributed to ADE experiment. KW, DL, and QW expressed SARS-CoV-2 623
- pseudovirus and their mutants and purification antibodies. PJ contributed to B cell 624
- sorting. This project was supervised by YZ, TZ, JS, and YMW. JH, FW, QZ, LL, RY, 625
- ML, ZL, and YDW analyzed the data and wrote the manuscript. 626

Acknowledgments

627

628

- We thank Prof. Zhengli Shi for helpful discussion and thank Dr. Vanessa M. Hirsch in 629
- NIH, USA for reviewing this manuscript. This work was supported by the National 630
- Natural Science Foundation of China (31771008 to JH, 31930001 to YZ and FW, 631
- 82041025 to SJ, and 31971123 to QZ), the National Major Science and Technology 632
- Projects of China (2017ZX10202102 to JH and 2018ZX10301403 to FW and 633
- LL), Hundred Talent Program of Shanghai Municipal Health Commission (2018BR08 634
- to JH), Chinese Academy of Medical Sciences (2019PT350002 to JH), Program of 635
- 636 Shanghai Academic/Technology Research Leader (20XD1420300 to LL), the Key
- R&D Program of Zhejiang Province (2020C04001), the SARS-CoV-2 Emergency 637
- Project of the Science and Technology Department of Zhejiang Province (2020C03129), 638
- the Leading Innovative and Entrepreneur Team Introduction Program of Hangzhou, and 639
- the Special Research Program of Novel Coronavirus Pneumonia of Westlake University 640
- and Tencent foundation to QZ. We thank all healthcare personnel and staff in the BSL3 641
- 642 lab involved in the collection of patients' samples at the Shanghai Public Health Clinical
- Center, the Cryo-EM Facility and Supercomputer Center of Westlake University for 643
- providing cryo-EM and computation support and members of the Core Facility of 644
- Microbiology and Parasitology (SHMC) of Fudan University, especially Qian Wang for 645
- technical support. 646

647

648

References

- 649 Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational 650 Update, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-
- reports/> (651
- 652 2 Draft landscape of COVID-19 candidate https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate- 653
- 654 vaccines> (
- 655 3 Yang, J. et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces 656 protective immunity. Nature, doi:10.1038/s41586-020-2599-8 (2020).
- 657 Zhu, F. C. et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored 4 658 COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, 659 placebo-controlled, phase 2 trial. Lancet 396, 479-488, doi:10.1016/S0140-
- 660 6736(20)31605-6 (2020).
- 661 Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 662 806-811, doi:10.1126/science.abc6284 (2020).

eserved. No		

663	6	Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against
664		SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled
665		trial. Lancet 396 , 467-478, doi:10.1016/S0140-6736(20)31604-4 (2020).

- Liu, L. *et al.* Anti-spike IgG causes severe acute lung injury by skewing macrophage
 responses during acute SARS-CoV infection. *JCI Insight* 4, doi:10.1172/jci.insight.123158
 (2019).
- Honda-Okubo, Y. *et al.* Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. *J Virol* **89**, 2995-3007, doi:10.1128/JVI.02980-14 (2015).
- Hashem, A. M. *et al.* A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model. *J Infect Dis* **220**, 1558-1567, doi:10.1093/infdis/jiz137 (2019).
- 677 10 Agrawal, A. S. *et al.* Immunization with inactivated Middle East Respiratory Syndrome 678 coronavirus vaccine leads to lung immunopathology on challenge with live virus. *Hum* 679 *Vaccin Immunother* **12**, 2351-2356, doi:10.1080/21645515.2016.1177688 (2016).
- Jiang, S. Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. *Nature* **579**, 321, doi:10.1038/d41586-020-00751-9 (2020).
- Tirado, S. M. & Yoon, K. J. Antibody-dependent enhancement of virus infection and disease. *Viral Immunol* **16**, 69-86, doi:10.1089/088282403763635465 (2003).
- Taylor, A. *et al.* Fc receptors in antibody-dependent enhancement of viral infections. *Immunol Rev* **268**, 340-364, doi:10.1111/imr.12367 (2015).
- Katzelnick, L. C. *et al.* Antibody-dependent enhancement of severe dengue disease in humans. *Science* **358**, 929-932, doi:10.1126/science.aan6836 (2017).
- Bardina, S. V. *et al.* Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. *Science* **356**, 175-180, doi:10.1126/science.aal4365 (2017).
- Halstead, S. B. Neutralization and antibody-dependent enhancement of dengue viruses.
 Adv Virus Res 60, 421-467, doi:10.1016/s0065-3527(03)60011-4 (2003).
- Vennema, H. *et al.* Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. *J Virol* **64**, 1407-1409, doi:10.1128/JVI.64.3.1407-1409.1990 (1990).
- Wu, F. *et al.* Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. *JAMA Intern Med*, doi:10.1001/jamainternmed.2020.4616 (2020).
- 698 19 Long, Q. X. *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med* 699 **26**, 845-848, doi:10.1038/s41591-020-0897-1 (2020).
- 700 20 Arvin, A. M. *et al.* A perspective on potential antibody-dependent enhancement of SARS-701 CoV-2. *Nature* **584**, 353-363, doi:10.1038/s41586-020-2538-8 (2020).
- Sariol, A. & Perlman, S. Lessons for COVID-19 Immunity from Other Coronavirus Infections. *Immunity* **53**, 248-263, doi:10.1016/j.immuni.2020.07.005 (2020).
- 704 22 Shen, C. *et al.* Treatment of 5 Critically III Patients With COVID-19 With Convalescent 705 Plasma. *JAMA* **323**, 1582-1589, doi:10.1001/jama.2020.4783 (2020).

706	23	Administration, U. F. a. D. Recommendations for Investigational COVID-19 Convalescent
707		Plasma, < https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-
708		or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-
709		convalescent-plasma > (

- 710 24 Jaume, M. et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies 711 trigger infection of human immune cells via a pH- and cysteine protease-independent 712 FcgammaR pathway. J Virol 85, 10582-10597, doi:10.1128/JVI.00671-11 (2011).
- 713 25 Bournazos, S., Gupta, A. & Ravetch, J. V. The role of IgG Fc receptors in antibody-714 dependent enhancement. Nat Rev Immunol. doi:10.1038/s41577-020-00410-0 (2020).
- 715 Byrd, T. F. & Horwitz, M. A. Chloroquine inhibits the intracellular multiplication of 26 716 Legionella pneumophila by limiting the availability of iron. A potential new mechanism for 717 the therapeutic effect of chloroquine against intracellular pathogens. J Clin Invest 88, 351-718 357, doi:10.1172/JCI115301 (1991).
- 719 27 Xia, S. et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent 720 pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity 721 to mediate membrane fusion. Cell Res 30, 343-355, doi:10.1038/s41422-020-0305-x 722 (2020).
- 723 28 Li, Q. et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and 724 Antigenicity. Cell 182, 1284-1294 e1289, doi:10.1016/j.cell.2020.07.012 (2020).
- 725 29 Korber, B. et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases 726 Infectivity of the COVID-19 Virus. Cell 182, 812-827 e819, doi:10.1016/j.cell.2020.06.043 727 (2020).
- 728 Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 30 729 2019. Clin Infect Dis, doi:10.1093/cid/ciaa344 (2020).
- 730 Pontelli, M. et al. Infection of human lymphomononuclear cells by SARS-CoV-2. bioRxiv, 31 731 doi:doi:10.1101/2020.07.28.225912 (2020).
- 732 32 Wang, Q. et al. Immunodominant SARS Coronavirus Epitopes in Humans Elicited both 733 Enhancing and Neutralizing Effects on Infection in Non-human Primates. ACS Infect Dis 734 2, 361-376, doi:10.1021/acsinfecdis.6b00006 (2016).
- 735 Du, L. et al. The spike protein of SARS-CoV--a target for vaccine and therapeutic 33 736 development. Nat Rev Microbiol 7, 226-236, doi:10.1038/nrmicro2090 (2009).
- 737 Tetro, J. A. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect 22, 72-34 738 73, doi:10.1016/j.micinf.2020.02.006 (2020).
- 739 35 Huang, J. et al. Isolation of human monoclonal antibodies from peripheral blood B cells. 740 Nat Protoc 8, 1907-1915, doi:10.1038/nprot.2013.117 (2013).
- 741 36 Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by 742 single cell RT-PCR and expression vector cloning. Journal of immunological methods 329, 743 112-124, doi:10.1016/j.jim.2007.09.017 (2008).
- 744 Georgiev, I. S. et al. Delineating antibody recognition in polyclonal sera from patterns of 37 745 HIV-1-isolate neutralization. Science, in press (2013).
- 746 38 Tian, X. et al. Potent binding of 2019 novel coronavirus spike protein by a SARS 747 coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 9, 382-385, 748 doi:10.1080/22221751.2020.1729069 (2020).
- 749 Lei, J. & Frank, J. Automated acquisition of cryo-electron micrographs for single particle 39

perpetuity.
All rights reserved. No reuse allowed without permission.

750	reconstruction on an FEI Tecnai electron microscope. Journal of structural biology 150,
751	69-80, doi:10.1016/j.jsb.2005.01.002 (2005).

- 752 40 Zheng, S. Q. *et al.* MotionCor2: anisotropic correction of beam-induced motion for 753 improved cryo-electron microscopy. *Nature methods* **14**, 331-332, doi:10.1038/nmeth.4193 (2017).
- Grant, T. & Grigorieff, N. Measuring the optimal exposure for single particle cryo EM using a 2.6 A reconstruction of rotavirus VP6. *eLife* **4**, e06980, doi:10.7554/eLife.06980 (2015).
- 757 42 Zhang, K. Gctf: Real-time CTF determination and correction. *Journal of structural biology* 758 **193**, 1-12, doi:10.1016/j.jsb.2015.11.003 (2016).
- 759 43 Zivanov, J. *et al.* New tools for automated high-resolution cryo-EM structure determination in RELION-3. *eLife* **7**, doi:10.7554/eLife.42166 (2018).
- Kimanius, D., Forsberg, B. O., Scheres, S. H. & Lindahl, E. Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2. *eLife* 5, doi:10.7554/eLife.18722 (2016).
- 764 45 Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure 765 determination. *Journal of structural biology* **180**, 519-530, doi:10.1016/j.jsb.2012.09.006 766 (2012).
- Scheres, S. H. A Bayesian view on cryo-EM structure determination. *Journal of molecular biology* **415**, 406-418, doi:10.1016/j.jmb.2011.11.010 (2012).
- 769 47 Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid 770 unsupervised cryo-EM structure determination. *Nature methods* **14**, 290-296, 771 doi:10.1038/nmeth.4169 (2017).
- Rosenthal, P. B. & Henderson, R. Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. *Journal of molecular biology* **333**, 721-745 (2003).
- 775 49 Chen, S. *et al.* High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy.

 777 *Ultramicroscopy* **135**, 24-35, doi:10.1016/j.ultramic.2013.06.004 (2013).
- 778 50 Trabuco, L. G., Villa, E., Mitra, K., Frank, J. & Schulten, K. Flexible fitting of atomic structures 779 into electron microscopy maps using molecular dynamics. *Structure (London, England : 1993)* **16**, 673-683, doi:10.1016/j.str.2008.03.005 (2008).
- Fig. 781 Finally, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot.

 Acta crystallographica. Section D, Biological crystallography 66, 486-501, doi:10.1107/S0907444910007493 (2010).
- Adams, P. D. *et al.* PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta crystallographica. Section D, Biological crystallography* **66**, 213-221, doi:10.1107/S0907444909052925 (2010).

Figure legends

- Figure 1. Plasma from 8% of the recovered patients with mild COVID-19 and 76% of the recovered
- 791 patients with severe COVID-19 showed enhancement of SARS-CoV-2 infection through IgG Fc
- 792 with the engagement of FcrRII receptor.

787

788

(A) Clinical characteristics of COVID-19 recovered patients whose plasma showed ADE. (B) The enhancement of SARS-CoV-2, SARS-CoV, SARS-related RS3367, WIV-1 infection of Raji cells by 29 plasma samples from patients who recovered from mild COVID-19 (N=16, blue) or severe COVID-19 (N=13, red) are shown. Plasma from 10 uninfected donors was used as negative controls. For each plasma sample, the area under curve (AUC) of fold changes of enhancement was calculated. (C) The enhancement of SARS-CoV-2 infection of K562 cells by 29 plasma samples are shown. (D) The enhancement of SARS-CoV-2 infection of primary B cells by eight representative plasma samples are shown. (E) ADE of SARS-CoV-2 infection was mediated by plasma IgG with the engagement of FcrRII receptor. IgG purified from the ADE plasma was evaluated for enhancement of SARS-CoV-2 infection of Raji cells. IgG-depleted plasma was also evaluated. (F) ADE plasma or (G) IgG purified from ADE plasma (right) were evaluated for ADE on Raji cells in the presence or absence of anti-FcrRII antibody CD32. Comparison of age (H), disease duration (I), and hospital stay (J) of 29 patients whose plasma showed ADE effect and 193 patients whose plasma did not show ADE effect (green). P value was calculated using non-parametric t test.

Figure 2. ADE is more likely to develop in elderly patients with high titers of SARS-CoV-2 RBDand S1-specific antibodies.

(A) SARS-CoV-2 NAb titers (ID50) and (B) RBD, S1-, and S2-specific binding antibodies of 29 ADE patients and 193 Non-ADE patients are compared. P value was calculated using t test. (C) Kinetics of SARS-CoV-2-specific ADE in plasma of six COVID-19 patients are shown. Plasma was collected at different time points post-disease onset. (D) Kinetics of spike-binding antibodies (left Y axis) targeting RBD, S1, and S2 in plasma of six COVID-19 patients exhibiting ADE are shown. Plasma diluted 1:400 was incubated with RBD, S1, or S2 protein. (E) Kinetics of SARS-CoV-2 NAbs titers in plasma of six COVID-19 patients whose plasma showed ADE are shown.

Figure 3. ADE was mediated by antibodies binding to SARS-CoV-2 spike RBD subunits.

(A) Suppression of ADE of plasma by RBD (A) or S1 protein (B) of SARS-CoV-2 but not by RBD (C) or S1 protein (D) of SARS-CoV viruses. Serially diluted patient plasma were pre-incubated with different concentrations of proteins before evaluating ADE of SARS-CoV-2 infection of Raji cells. Untreated plasma was used as a positive control, and healthy donor plasma was used as a negative control. (E) ADE mediated by plasma from six patients was inhibited by pre-incubation with 10 μg/ml SARS-CoV-2 RBD but not SARS-CoV RBD.

Figure 4. ADE-mediated SARS-CoV-2 entry into cells is through virus-cell membrane fusion.

Inhibition of ADE induced by plasma from patients using chloroquine (A) or EK peptide (B). Serially diluted plasma was pre-incubated with different concentrations of chloroquine or EK1 peptide before evaluating ADE of SARS-CoV-2 infection of Raji cells. Patient plasma with ADE was used as a positive control, and plasma from uninfected health donor was used as a negative control. (C) ADE mediated by plasma from six patients was inhibited by 50 µM of EK1 peptide but not by chloroquine.. (D) ADE plasma from recovered COVID-19 patients promoted syncytium formation. Plasma from uninfected health donor was used as a negative control. The syncytium formation was specifically inhibited by EK1 peptide but not by chloroquine. (E) The statistical counts of syncytium formation induced by plasma from three patients (8, 5, and 7) in the presence of EK1 peptide or chloroquine.

793

794

795

796

797

798

799

800

801 802

803

804

805

806

807 808

809

810

811 812

813 814

815

816

817

818 819

820

821

822

823

824

825 826

827

828

829

830

831

832

833

834

835

- Figure 5. RBD-specific NAb 7F3 from a recovered patient of COVID-19 enhanced SARS-CoV-2
- 838 entry into cells through virus-cell membrane fusion.

837

847 848

854

862 863


- 839 (A) Neutralizing curve of 7F3 and 4L12 against SARS-CoV-2 pseudovirus. (B) Binding of 7F3 and 4L12
- 840 mAb to SARS-CoV-2 RBD, S1, and S2 proteins in ELISA assay. (C) Binding affinity of 7F3 and 4L12
- 841 to RBD was measured by bilayer interferometry experiments. (D) Enhancement of SARS-CoV-2
- 842 infection of Raji cells by 7F3 but not by 4L12. (E) Impact of IgG, Fab, and Fc of 7F3 on ADE of SARS-
- CoV-2 infection. (F) Impact of IgG1, IgG2, IgG3, and IgG4 isotypes of 7F3 on ADE of SARS-CoV-2 843
- 844 infection. (G) Blockage of RcrRII with anti-CD32 antibody (5 µg/mL) inhibited ADE induced by 7F3.
- (H) RBD of SARS-CoV-2 (left) blocked ADE induced by 7F3. RBD of SARS-CoV (right) was used as 845
- 846 a negative control. (I) Blockage of ADE induced by 7F3 with EK1 (left) and chloroquine (right).
 - Figure 6. Peptide scanning for hot spots in RBD associated with ADE effect.
- 849 ADE of patient plasma (A) and antibody 7F3 (B) were blocked with 20-mer overlapping peptides
- 850 covering RBD protein. Serially diluted ADE patient plasma was pre-incubated with 20 µg/ml peptides
- 851 before evaluating ADE effect on Raji cells. Patient plasma with ADE was used as a positive control, and
- 852 plasma from uninfected health donor was used as a negative control. (C) Percentage of AUC changes of
- 853 ADE curves after blocking of ADE patient plasma and 7F3 with 20-mer RBD overlapping peptides.
- 855 Figure 7. ADE antibody 7F3 and non-ADE antibody 4L12 shared overlapping epitopes but showed
- 856 different binding abilities to RBD.
- (A) Neutralization potency and breadth of antibodies against 27 SARS-CoV-2 RBD mutants. Mutants 857
- reported to be resistant to SARS-CoV-2 NAbs were highlighted in blue. (B) Percentage of 7F3 or 4L12 858
- 859 binding to SARS-CoV-2 RBD mutants compared with RBD WT. Values between 0.5 - 0.8 are highlighted
- 860 in yellow, and values < 0.5 are highlighted in red. (C) Binding curves of 7F3 or 4L12 to SARS-CoV-2
- 861 RBD and its mutants.
 - Figure 8. Structures of 7F3 or 4L12 in complex with the S protein of SARS-CoV-2 revealed
- 864 different binding patterns.
- 865 (A) Cryo-EM structure of the 7F3-bound S protein. 7F3 binds to one "up" RBD and one "down" RBD.
- 866 (B) Cryo-EM structure of the 4L12-bound S protein. The insets in (A) and (B) show the details of the
- 867 corresponding regions. (C) 7F3 shifts for about 28.5 angstroms compared with 4L12. (D) The ACE2
- 868 binding site and the epitopes of 7F3 and 4L12 on RBD of the S protein. The complexes of RBD with
- 869 ACE2 and the antibody 7F3 and 4L12 are shown as cartoon in left column. The RBD is shown as grey
- 870 surface in middle column, with the ACE2 binding site colored in green and the epitope of 7F3 and 4L12
- 871 colored in orange and pink, respectively. In the right column, the antibodies are shown as surface, with
- 872 the heave and light chains colored as in (A) and the paratopes colored in grey.
- 874 Figure 9. Scheme of dual effects of SARS-CoV-2 neutralizing antibodies on mediating both
- 875 neutralization and ADE.
- 876 (A) Binding of NAbs to RBD of SARS-CoV-2 spike protein blocks virus from infecting ACE2 receptor
- 877 expressing cells. (B) Binding of NAbs to Fc receptors (FcRs) expressing immune cells with their Fc
- 878 domains and to the RBD with their Fab domains triggers fusion-based viral infection.


Α

ADE

Non-ADE

Patient Information	М	Mild COVID-19			Severe COVID-19		
Patient information	Total	Non-ADE	ADE	Total	Non-ADE	ADE	patients
Patient No. (%)	205 (100)	189 (92)	16 (8)	17 (100)	4 (24)	13 (76)	222
Male (%)	102 (50)	97 (47)	5 (3)	12 (70)	2 (12)	10 (58)	114
Female (%)	103 (50)	92 (45)	11 (5)	5 (30)	2 (12)	3 (18)	108
Median Age (Years)	51 [37-64]	50 [37-63]	63 [44-66]	66 [64-78]	66 [64-70]	69 [64-80]	53 [38-65]
Length of stay (days)	17 [13-23]	16 [13-22]	20 [16-26]	50 [33-72]	27 [25-32]	57 [40-75]	17 [13-24]
Disease duration (days)	22 [18-29]	22 [18-28]	25 [22-31]	58 [39-75]	32 [30-37]	61 [46-79]	23 [18-30]







ADE


Non-ADE


ADE


Non-ADE














4	r	•	
Ī	L	•	
	Ī		

Peptide	eptide Pontido soguenco		AUC change (%)		
ID	Peptide sequence	S1 region	Plasma	7F3 mAb	
1	KSFTVEKGIY QTSNFRVQPT	304-323	85	82	
2	QTSNFRVQPT ESIVRFPNIT	314-333	24	42	
3	ESIVRFPNIT NLCPFGEVFN	324-343	27	33	
4	NLCPFGEVFN ATRFASVYAW	334-353	37	27	
5	ATRFASVYAW NRKRISNCVA	344-363	42	33	
6	NRKRISNCVA DYSVLYNSAS	354-373	45	40	
7	DYSVLYNSAS FSTFKCYGVS	364-383	74	90	
8	FSTFKCYGVS PTKLNDLCFT	374-393	22	33	
9	PTKLNDLCFT NVYADSFVIR	384-403	75	31	
10	NVYADSFVIR GDEVRQIAPG	394-413	10	12	
11	GDEVRQIAPG QTGKIADYNY	404-423	13	23	
12	QTGKIADYNY KLPDDFTGCV	414-433	15	21	
13	KLPDDFTGCV IAWNSNNLDS	424-443	36	32	
14	IAWNSNNLDS KVGGNYNYLY	434-453	18	37	
15	KVGGNYNYLY RLFRKSNLKP	444-463	24	36	
16	RLFRKSNLKP FERDISTEIY	454-473	61	52	
17	FERDISTEIY QAGSTPCNGV	464-483	0	42	
18	QAGSTPCNGV EGFNCYFPLQ	474-493	27	43	
19	EGFNCYFPLQ SYGFQPTNGV	484-503	63	52	
20	SYGFQPTNGV GYQPYRVVVL	494-513	43	46	
21	GYQPYRVVVL SFELLHAPAT	504-523	39	34	
22	SFELLHAPAT VCGPKKSTNL	514-533	13	35	
23	VCGPKKSTNL VKNKCVNFNF	524-543	52	49	
24	VKNKCVNFNF NGLTGTGVLT	534-553	33	43	
25	NGLTGTGVLT ESNKKFLPFQ	544-563	95	83	
26	ESNKKFLPFQ QFGRDIADTT	554-573	88	46	
27	QFGRDIADTT DAVRDPQTLE	564-583	95	82	
28	DAVRDPQTLE ILDITPCSFG	574-593	96	79	

٠,		
4	,	
	1	2

Muants \ mAb	IC50 (µg/ml)		ge relative WT
	7F3	4L12	7F3	4L12
SARS2 WT	0.00684	0.00452	1	1
V341I	0.01569	0.03091	2	7
F342L	>50	>50	7309	11072
V367F	0.00771	0.00585	1	1
F374A	0.01368	0.00862	2	2
R408I	0.00675	0.00373	1	1
D427A	0.03808	0.01445	6	3
A435S	0.00318	0.00434	0.5	1
N439K	0.02427	0.01533	4	3
N450G	0.00503	0.00612	1	1
L452R	0.00571	0.01573	1	3
P463A	0.01800	0.02760	3	6
1472V	0.00020	0.01140	0	3
A475V	0.00878	0.01915	1	4
G476S	0.01044	0.01828	2	4
S477A	0.02524	0.00703	4	2
V483A	0.00467	0.00723	1	2
F490L	0.00530	0.00843	1	2
P491A	>50	>50	7309	11072
G504N	0.00824	0.00421	1.2	1
Y508H	0.00262	0.01541	0.4	3
E516A	>50	>50	7309	11072
L517A	0.00896	0.00841	1	2
D614G	0.00609	0.01293	1	3
A831V	0.00559	0.00945	1	2
No. of mutants	25	25		
IC ₅₀ <50 µg/ml	88%	88%		
IC ₅₀ <1 μg/ml	88%	88%		
GM IC ₅₀ *	0.007	0.010		
Median IC ₅₀	0.007	0.009		

*	Geometric	Mean	IC50	concentration	is ua/ml

RBD protein	% of Pinding	rolativo to M/T
mutants		relative to WT
WT RBD-Fc	7F3 1.00	4L12 1.00
Q321L	1.00	1.00
T323A	1.00	1.00
F342L	0.91	0.93
V367F	1.00	1.00
V367A	1.00	1.00
A372T	1.03	1.04
F374A	1.02	0.84
S375A	1.03	0.97
T376A	1.02	0.90
F377A	1.03	0.92
S383A	1.06	0.96
P384A	1.05	0.89
T385A	1.00	0.89
K386A	0.99	0.84
F392A	1.00	0.88
Q414E	0.99	1.00
D427A	0.90	0.63
D428A	1.04	0.91
A435G	0.92	0.94
N439K	1.00	0.98
G446V	0.98	0.97
N451G	1.00	1.01
L452R	1.00	0.99
K458N	0.99	1.00
1472V	0.98	1.02
A475V	0.99	0.96
T478I	1.00	1.02
V483A	0.99	0.99
V483I	1.00	1.00
F490L	0.98	0.96
P491A	0.06	0.06
G504N	1.00	0.99
Y508H	0.99	1.00
E516A	1.02	0.85
L517A	1.00	0.83
H519P	1.01	1.00
QT414-415AA	1.01	0.94
NNL439-441AAA	1.01	0.90
NYN448-450AAA	0.92	0.71
GST476-478AAA	0.95	0.65
NGV481-483AAA	0.93	0.65
NGV500-502AAA	1.00	0.05
YQP504-506AAA	0.96	0.48
. 4. 00 . 000/1/1/	0.00	0.40




Figure 8





Figure 9



Supplementary Table and Figures

Table S1. Cryo-EM data collection and refinement statistics.

EM equipment Titan Krios (Therm Fisher Scientific) Voltage (kV) 300 Detector Gatan GI S usmit Energy filter Gatan GIF Quartum, 20 eV slit Pixel size (Å) 1.087 Electron dose (e-/Å2) 5 - 1.087 Defocus range (µm) -1.22.2 Sample S-ECD+Ab7F3 S-ECD+Ab4L12 Number of selected micrographs 1,877 1,219 Number of selected micrographs 1,840 1,199 Software Retirement Sample Overall subcomplex Overall subcomplex Overall subcomplex Overall subcomplex Overall subcomplex Overall subcomplex Software Cl Cl Cl Cl Subcomplex Subcomplex Subcomplex Subcomplex Subc	Data collection				
Detector Gatan GIF Quantum, 20 eV slit Pixel size (Å) 1.087 Electron dose (e-Å2) 5.0 Defocus range (μm) - 2.2 - 2.2 Sample S-ECD+Ab7F3 S-ECD+Ab4L12 Number of collected micrographs 1,877 1,219 Number of selected micrographs 1,840 1,1219 Number of selected micrographs 1,840 1,219 Software Software Number of used particles (Overall) 9,903 2,904 9 (verall) subcomplex Number of used particles (Overall) 91,303 29,903 314,098 557,717 Resolution (Å) 3,3 6,3 3,508 557,717 Refinement Software Phene (A) 3,508 4,308 4,308 4,308 4,308 4,308 6,430 6,430 6,430<	EM equipment	Titan Krios (Thermo Fisher Scientific)			
Energy filter Gatan GIF Quantum, 20 eV slit Pixel size (Å) 1.087 Electron dose (e-/Å2) 5 - C - Ab T - A - 2.2 Defocus range (μm) -1.2 - 2.2 Sample S-ECD+Ab7F3 S-ECD+Ab4L12 Number of collected micrographs 1,877 1,219 Number of selected micrographs 1,840 1,199 3D Reconstruction Software Reformance Subcomplex Overall subcomplex Number of used particles (Overall) 91,303 29,903 314,098 557,717 Resolution (Å) 3.3 6.3 1 1 Refinement Supmetry C I Map sharpening B-factor (Å2) 3 5 Pretix Software Pcl didmensions a = b-c (Å) 3 313.056 4 308 3	Voltage (kV)	300			
Pixel size (Å) 1.087 Electron dose (e-/Å2) 50 Defocus range (μm) -1.2 ~ -2.2 Sample S-ECD+Ab7F3 S-ECD+Ab4L12 Number of collected micrographs 1,877 1,219 Number of selected micrographs 1,840 1,199 3D Reconstruction Software Relimant 3.0 subcomplex Sample Overall subcomplex Overall subcomplex Number of used particles (Overall) 91,303 29,903 314,098 557,717 Resolution (Å) 3.3 6.3 3.0 3.5 Symmetry Cl L V Map sharpening B-factor (Å2) 3.2	Detector	Gatan K3 Summit			
Defocus range (μm)	Energy filter	Gatan GIF Quantum, 20 eV slit			
Defocus range (μm) 5-ECD+Ab7F3 S-ECD+Ab4L12 Number of collected micrographs 1,877 1,219 Number of selected micrographs 1,840 1,199 3D Reconstruction Software Resulus 3.0 Subcomplex Overall subcomplex Sample Overall subcomplex Overall subcomplex Number of used particles (Overall) 91,303 29,903 314,098 557,717 Resolution (Å) 3.3 6.3 3.0 3.5 Symmetry Image of Classifications Image of Class	Pixel size (Å)	1.087			
Sample S-ECD+Ab4F3 S-ECD+Ab4L12 Number of collected micrographs 1,877 1,219 Number of selected micrographs 1,840 1,199 3D Reconstruction Software Relion 3.0 Sample Overall subcomplex Overall subcomplex Sample Overall subcomplex Overall subcomplex Number of used particles (Overall) 91,303 29,903 314,098 557,717 Resolution (Å) 3.3 6.3 3.0 3.5 Symmetry Cl Cl The proportion The proportion The proportion The proportion The protein residues 3,508 4,308 4,308 4,308 The proportion The proportion proportion proportion The proportion proportio	Electron dose (e-/Å2)	50			
Number of collected micrographs 1,877 1,219 Number of selected micrographs 1,840 1,199 3D Reconstruction Software Religion of Software Sample Overall subcomplex Overall subcomplex Number of used particles (Overall) 91,303 29,903 314,098 557,717 Resolution (Å) 3.3 6.3 3.0 3.5 Symmetry □	Defocus range (µm)	-1.2 ~ -2.2			
Number of selected micrographs 1,840 1,199 3D Reconstruction Software Relimiter of subcomplex Overall overall subcomplex Overall overall subcomplex	Sample	S-ECD+Ab7F3 S-ECD+Ab4L12			
3D Reconstruction Software Relimant 3.0 Sample Overall subcomplex Overall subcomplex Number of used particles (Overall) 91,303 29,903 314,098 557,717 Resolution (Å) 3.3 6.3 3.0 3.5 Symmetry CI -90 -90 Refinement Software Phenix	Number of collected micrographs	1,877		1,219	
Software Overall subcomplex Overall overall subcomplex Overall overall overall overall subcomplex Number of used particles (Overall) 91,303 29,903 314,098 557,717 Resolution (Å) 3.3 6.3 3.0 3.5 Symmetry CI Image: CI	Number of selected micrographs	1,840		1,199	
Sample Overall operation (Number of used particles (Overall) 91,303 (29,903) 314,098 (314,098) 557,717 Resolution (Å) 3.3 6.3 3.0 3.5 Symmetry C1 -90 -90 Map sharpening B-factor (Å2) Fefinement -90 -90 Software Phenix -90 -90 Cell dimensions -90 -90 -90 Model cell dimensions -90 -90 -90 Model composition -90 -90 -90 Model composition -90 -90 -90 Protein residues 3,508 4,308 -90 Side chains assigned 3,458 4,308 -90 Sugar 71 71 71 RMS deviations -90 0.007 0.007 Bond lengths (Å) 0.009 0.0720 Ramachandran plot statistics (%) 91.26 Preferred 88.80 91.26 Allowed 10.90 8.60	3D Reconstruction				
Number of used particles (Overall) 91,303 29,903 314,098 557,717 Resolution (Å) 3.3 6.3 3.0 3.5 Symmetry C1 Map sharpening B-factor (Å2) -90 Refinement Software Phenix Cell dimensions 313.056 $\alpha = \beta = c$ (Å) 313.056 $\alpha = \beta = \gamma$ (°) 90 Model composition 90 Protein residues 3,508 4,308 Side chains assigned 3,458 4,308 Sugar 71 71 RMS deviations 80nd lengths (Å) 0.009 0.007 Bond Angles (°) 0.795 0.720 Ramachandran plot statistics (%) 88.80 91.26 Allowed 10.90 8.60	Software	Relion 3.0			
Resolution (Å) 3.3 6.3 3.0 3.5 Symmetry C1 Map sharpening B-factor (Å2) -90 Refinement Software Phenix Cell dimensions 313.056 $\alpha = \beta = \gamma$ (°) 90 Model composition 90 Protein residues 3,508 4,308 Side chains assigned 3,458 4,308 Sugar 71 71 RMS deviations 801 lengths (Å) 0.009 0.007 Bond lengths (Å) 0.009 0.720 Ramachandran plot statistics (%) 91.26 Allowed 10.90 8.60	Sample	Overall	subcomplex	Overall	subcomplex
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Number of used particles (Overall)	91,303	29,903	314,098	557,717
Map sharpening B-factor (Å2)-90RefinementPhenixSoftwarePhenixCell dimensions 313.056 $a=b=c$ (Å) 313.056 $\alpha=\beta=\gamma$ (°)90Model composition $4,308$ Protein residues $3,508$ $4,308$ Side chains assigned $3,458$ $4,308$ Sugar 71 71 RMS deviations 71 71 Bond lengths (Å) 0.009 0.007 Bond Angles (°) 0.795 0.720 Ramachandran plot statistics (%) 91.26 Preferred 88.80 91.26 Allowed 10.90 8.60	Resolution (Å)	3.3	6.3	3.0	3.5
Refinement Software Phenix Cell dimensions 313.056 $\alpha = \beta = \gamma$ (°) 90 Model composition 90 Protein residues 3,508 4,308 Side chains assigned 3,458 4,308 Sugar 71 71 RMS deviations 71 71 Bond lengths (Å) 0.009 0.007 Bond Angles (°) 0.795 0.720 Ramachandran plot statistics (%) 91.26 Allowed 10.90 8.60	Symmetry	C1			
Software Phenix Cell dimensions 313.056 $\alpha = \beta = \gamma$ (°) 90 Model composition Protein residues Protein residues 3,508 4,308 Side chains assigned 3,458 4,308 Sugar 71 71 RMS deviations Bond lengths (Å) 0.009 0.007 Bond Angles (°) 0.795 0.720 Ramachandran plot statistics (%) Preferred 88.80 91.26 Allowed 10.90 8.60	Map sharpening B-factor (Å2)	-90			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Refinement				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Software	Phenix			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Cell dimensions				
Model composition Protein residues 3,508 4,308 Side chains assigned 3,458 4,308 Sugar 71 71 RMS deviations 3,458 4,308 Bond lengths (Å) 0.009 0.007 Bond Angles (°) 0.795 0.720 Ramachandran plot statistics (%) 91.26 Allowed 10.90 8.60	a=b=c (Å)	313.056			
Protein residues 3,508 4,308 Side chains assigned 3,458 4,308 Sugar 71 71 RMS deviations 3,508 4,308 Bond lengths (Å) 0.009 0.007 Bond Angles (°) 0.795 0.720 Ramachandran plot statistics (%) 91.26 Allowed 10.90 8.60	α=β=γ (°)	90			
Side chains assigned 3,458 4,308 Sugar 71 71 RMS deviations Bond lengths (Å) 0.009 0.007 Bond Angles (°) 0.795 0.720 Ramachandran plot statistics (%) Preferred 88.80 91.26 Allowed 10.90 8.60	Model composition				
Sugar 71 71 RMS deviations 0.009 0.007 Bond lengths (Å) 0.009 0.720 Bond Angles (°) 0.795 0.720 Ramachandran plot statistics (%) 91.26 Allowed 10.90 8.60	Protein residues		3,508		4,308
RMS deviations Bond lengths (Å) 0.009 0.007 Bond Angles (°) 0.795 0.720 Ramachandran plot statistics (%) Preferred 88.80 91.26 Allowed 10.90 8.60	Side chains assigned		3,458	4,308	
Bond lengths (Å) 0.009 0.007 Bond Angles (°) 0.795 0.720 Ramachandran plot statistics (%) Preferred 88.80 91.26 Allowed 10.90 8.60	Sugar		71		71
Bond Angles (°) 0.795 0.720 Ramachandran plot statistics (%) Preferred 88.80 91.26 Allowed 10.90 8.60	RMS deviations				
Ramachandran plot statistics (%) Preferred 88.80 91.26 Allowed 10.90 8.60	Bond lengths (Å)		0.009		0.007
Preferred 88.80 91.26 Allowed 10.90 8.60	Bond Angles (°)		0.795		0.720
Allowed 10.90 8.60	Ramachandran plot statistics (%)				
	Preferred		88.80		91.26
Outlier 0.30 0.13	Allowed		10.90		8.60
	Outlier		0.30		0.13

1




Figure S1. Enhancement of SARS-CoV-2 infection of Raji cells by patient plasma.

- 6 (A) 29 plasma from patients recovered from mild (1-16) and severe COVID-19 (17-
- 7 29) showed enhancement of SARS-CoV-2 infection of Raji cells. Ten plasma from
- 8 uninfected donors were used as controls. Plasma samples were two-fold serially diluted
- 9 and tested for ADE of SARS-CoV-2 infection of Raji cells. The assay was performed
- 10 in duplicate wells and mean fold changes of luciferase reading comparing to virus
- 11 control are shown.




Figure S2. Enhancement of SARS-CoV-2 infection of K562 cells by COVID-19 12

13 patient plasma.

- 14 29 plasma from patients who recovered from mild (1-16) and severe COVID-19 (17-
- 15 29) showed enhancement of SARS-CoV-2 infection of K562 cells. Four plasma from
- 16 uninfected donors were used as controls. The assay was performed in duplicate wells
- 17 and mean fold changes of luciferase reading comparing to virus control are shown.




Figure S3. Enhancement of SARS-CoV-2 infection of primary B cells by COVID-

19 patient plasma.

19

20

- Eight representative plasma from patients with mild COVID-19 (3, 4, 6, and 8) and 21
- 22 severe COVID-19 (21, 23, 26, and 28) showed enhancement of SARS-CoV-2 infection
- 23 of primary B cells. Four plasma from uninfected donors were used as controls.




Figure S4. Comparison of ADE effect in plasma from uninfected control donors and uninfected older donors.




Figure S5. Kinetics of SARS-CoV-2 ADE, spike-binding antibodies and NAbs

39 (A) Kinetics of SARS-CoV-2 ADE effect of six ADE patients are shown. Kinetics of

spike-binding antibodies (right Y axis), targeting RBD (brown), S1 (green), and S2


(blue) (B) and kinetics of NAbs (right Y axis, blue) (C) in six COVID-19 patient plasma

42 are shown and compared with the kinetics of ADE effect (left Y axis, red) in the same

43 patient. 1:400 diluted plasma was incubate with RBD, S1, or S2 protein.

38

40



(A)-(B) Representative SEC purification profile of the S-ECD of SARS-CoV-2 in complex with Ab7F3 and Ab4L12, respectively. (C) Euler angle distribution in the final 3D reconstruction of S-ECD of SARS-CoV-2 bound with Ab7F3 complex. (D) and (E) Local resolution maps for the 3D reconstruction of the overall structure and RBD-Ab7F3 subcomplex, respectively. (F) FSC curve of the overall structure (blue) and RBD-Ab7F3 subcomplex (orange). (G) FSC curve of the refined model of S-ECD of

Figure S6. Cryo-EM analysis of S-ECD of SARS-CoV-2 bound with 4A8 complex.

46

47

48

49

50

51

52

53

SARS-CoV-2 bound with Ab7F3 complex versus the overall structure against which it

55

56

57

58

59

60

is refined (black); of the model refined against the first half-map versus the same map (red); and of the model refined against the first half-map versus the second half-map (green). The small difference between the red and green curves indicates that the refinement of the atomic coordinates lacks sufficient overfitting. (H) FSC curve of the refined model of RBD-Ab7F3 subcomplex, which is the same as (G). (I)-(N) is the same as **(C)-(H)**, except for SARS-CoV-2 bound with Ab4L12 complex.




Figure S7. Representative cryo-EM image and flowchart for cryo-EM data processing.

- 64 (A) Representative cryo-EM micrograph and 2D class averages of cryo-EM particle
- images. The scale bar in 2D class averages is 10 nm. (B) Please refer to the 'Data 65
- 66 Processing' section in Methods for details.




Figure S8. Overall maps of S-ECD in complex with mAb and representative cryo-EM density maps.

68

69

70

71

72

73

74

(A) The domain-colored cryo-EM maps of S-ECD of SARS-CoV-2 bound with Ab7F3 complex. (B) The domain-colored cryo-EM maps of S-ECD of SARS-CoV-2 bound with Ab4L12 complex. (C) Cryo-EM density map for S-ECD in complex with Ab7F3 is shown at threshold of 6 σ .




Figure S9. Structural alignment between RBD-mAb subcomplex and RBD-PD complex (PDB ID: 6M0J). (A) Superposition in local structure of "up" RBD-Ab7F3 subcomplex and "down" RBD-Ab7F3 subcomplex, indicating no difference between the two maps. (B) Structural alignment between RBD-Ab7F3 subcomplex and RBD-PD complex (PDB

ID: 6M0J). (C) Structural alignment between RBD-Ab7F3 subcomplex and RBD-PD

75

76

77

78

79

80

81

82

83

complex (PDB ID: 6M0J).




Figure S8. Interactions between the RBD and Ab4L12.

- 86 (A) Extensive hydrophilic interactions on the interface between RBD and Ab4L12.
- 87 (B) and (C) Detailed analysis of the interface between RBD and Ab 4L12. Polar
- 88 interactions are indicated by red dashed lines.

85